{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Gastrointestinal toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Neurologic toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Cardiac toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Hematological toxicity"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Number of Grade 3/4 adverse events per the National Cancer Institute (NCI) Common Toxicity Criteria v 3.0.","groups":[{"description":"Initially patients will receive a dose of 500mg (2, 250mg tablets) in the morning and 250mg (1, 250mg tablet) in the afternoon for 2 weeks (cycle 1, days 1-14), then 500mg (2, 250mg tablets) bid for 2 weeks (cycle 1, days 15-28) and finally 750mg (3, 250mg tablets) in the morning and 500mg (2, 250mg tablets) in the afternoon for the remainder of treatment duration (cycle 2, day 1 and onwards). Each 28 days of drug administration will constitute one cycle of therapy.","id":"OG000","title":"PTK787/ZK 222584"}],"paramType":"NUMBER","populationDescription":"Only 13 out of the 21 participants experienced a grade 3 or 4 adverse event.","reportingStatus":"POSTED","timeFrame":"30 days after treatment ends [median of 15 cycles (11-32)]","title":"Safety and Tolerability of PTK787/ZK 222584","type":"SECONDARY","unitOfMeasure":"adverse events"}